Tracey Weiss, MPH
Articles
August 25th 2021
Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes
Manjiri Pawaskar, PhD S. Pinar Bilir, MS Stacey Kowal, MS Qianyi Li, MS Tracey Weiss, MPH Glenn Davies, DrPH
Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: April 30th 2018 | Updated: January 21st 2025
In Final Turn With Planned Parenthood, Cecile Richards Tells Obstetricians Women's Healthcare "Has a Long Way to Go"
